Videos |View More
Video
Meet the Team: Rohit Gosain, MD
“I threw away my circuit board and replaced with a stethoscope because I felt I was missing that human connection,” says Dr. Gosain, who recently became the Medical Director for Roswell Park Hematology Oncology Southtowns, in Orchard Park, NY.
Video
Watch: When to Think of Amyloidosis, How to Diagnose and Treat
Experts from Roswell Park Comprehensive Cancer Center joined with colleagues from the Boston University School of Medicine to discuss the latest information on amyloidosis, including recommendations for physicians on how to diagnose the ...
Video
Meet the Team: Hamza Hassan, MD
Hamza Hassan, MD, thinks the future is bright for patients with Myeloma and Amyloidosis. With encouraging research and treatment development opportunities, he moved from Boston to Buffalo to join the team at Roswell Park Comprehensive ...
Video
First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park
Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective therapeutic strategy for patients with B-cell lymphoid cancers.
Symposium
This CME-accredited activity, the Upstate New York Hematology & Hematologic Oncology Conference: Updates from the 65th ASH Annual Meeting, is a two-day symposium designed to provide an engaging and interactive forum for discussing the ...
Video
Meet the Team: Dr. Ehsan Malek
As the Director of the Multiple Myeloma Translational Research Program at Roswell Park, Dr. Malek brings with him a passion for finding new and innovative treatments for this disease and other plasma cell disorders
Video
Diagnosis and Co-management of Hematologic Malignancies for the Primary Care Provider
Our expert speakers dive into the latest techniques in diagnostics, treatment modalities, and interdisciplinary approaches, providing attendees with valuable insights to enhance patient care and outcomes.
Video
Updates and Advancements in Cellular Therapy at Roswell Park
Originally Broadcast: Thursday, November 9, 2023 6:00 - 7:30 PM EST - This program is intended for Hematologists, Oncologists, Pharmacists, Pathologists, and other healthcare professionals that care for cancer patients.
Symposium
The New York State Cellular Therapy Consortium
This is a clinically oriented educational program intended for hematologists, oncologists, pharmacists, pathologists, and other healthcare professionals that may diagnose, treat, or manage patients with cancer. The goal is to educate participants ...
News |View More
News
Exclusive to Roswell Park, ‘Armored CAR’ Clinical Trial Targets CD19+ Hematologic Malignancies
A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center will evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory hematologic malignancies whose tumor ...
News
Next Generation Armored Car T-Cell Therapy Trial Now Open
This Phase I/II trial will test the effectiveness, safety, side effects, and best dose of CD19-targeted Chimeric Antigen Receptor (CAR) modified T cells genetically engineered to secrete interleukin 12 (IL-12) in patients with hematologic B-cell malignancies.
News
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.
News
A team of researchers from Roswell Park Comprehensive Cancer Center, report that the efficacy of doxorubicin, a widely used chemotherapy drug, was enhanced in preclinical lymphoma models when it was combined with propranolol.
News
New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical ...
News
A single infusion of the CAR T cell therapy ciltacabtagene autoleucel produced deep, durable responses in multiple myeloma patients whose disease had progressed less than a year after autologous stem cell transplant (ASCT) or who experienced ...
News
Replacing brentuximab vedotin with nivolumab in first-line treatment combined with the chemotherapy regimen AVD improved progression-free survival in pediatric patients with newly diagnosed, advanced-stage classic Hodgkin lymphoma (cHL), ...
News
Clinical Trial Evaluates Triple-Drug Regimen for Patients Newly Diagnosed with FLT3-Mutated AML
Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis. To complicate matters, often they are ineligible for intensive ...
News
Because most multiple myeloma patients are 65 or older, including some who are frail, successive lines of therapy to address relapsed disease often take their toll — so keeping patients in deep remission after frontline treatment is highly desirable.
This site is intended for healthcare professionals
Download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.
BROADCASTMED